OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 221 - 230 of 796 studies

Oral and Gastrointestinal

Optimisation before Crohn's surgery using Exclusive Enteral Nutrition (OCEaN)

Crohn’s disease is a lifelong inflammatory illness that causes people to have severe stomach pains, chronic diarrhoea, and suffer weight loss. There is no cure. Crohn’s disease causes inflammation, ulceration, bleeding and narrowing of the digestive system. People can have periods of good health (“remission”) and times when symptoms are more active (“flare ups” or “relapses”). Medications can help keep it in remission, however one third of people will need surgery to remove/repair part of their diseased gut at some ...

GO TO STUDY Go

Inflammatory and immune system

Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis (PUMIA)

Controlling persistent pain is a significant unmet need for people living with Inflammatory arthritis (IA). There is emerging evidence that patients with IA exhibit different types of pain and central sensitisation contributes significantly to chronic pain. The treatment for different pain types will differ. One way in which we might rapidly improve the treatment of pain in IA is by identifying an individual’s pain type in the clinic, then tailor their pain treatment accordingly. Currently this is not routine practice and ...

GO TO STUDY Go

Cancer and neoplasms

Volatile Organic Compounds as Breath BIomarkers in Squamous Oesophageal Neoplasms (ViSON) (VISON)

Oesophageal squamous cell cancer (OSCC) is a cancer that grows in the food pipe and affects up to 2,000 people in the UK every year. Most patients are diagnosed when the cancer has spread to other body parts (advanced stage). As a result, the five-year survival is less than 20%. In comparison, when diagnosed early, nearly three out of four patients survive more than five years, indicating that early diagnosis improves survival. There are numerous challenges in detecting OSCC early. ...

GO TO STUDY Go

Infection

A dose finding human experimental infection study with SARS-CoV-2 Omicron BA.5 subvariant in healthy volunteers immunologically experienced against SARS-CoV-2 (COV-CHIM02)

The purpose of this study is to evaluate the safety and human clinical response to SARS-CoV-2 challenge with the omicron variant virus, in previously SARS-CoV-2 vaccinated people. We aim to establish the optimal challenge dose that causes re-infection and identify the lowest level of infectious dose necessary to produce viral replication in the upper respiratory tract of research volunteers while minimising risk of disease progression. Investigators aim to achieve an infection model which results in no symptoms, or symptoms no ...

GO TO STUDY Go

Blood

Graduated Compression stocking as an adjunct to Extended duration pharmacological thromboprophylaxis for venous thromboembolism prevention (GRACE)

Hospital-acquired thrombosis (HAT) is defined as any VTE within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key ...

GO TO STUDY Go

Oral and Gastrointestinal

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn’s Disease (MK7240-008)

This protocol includes 2 independent, multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (Study 1 and Study 2) to assess the efficacy and safety of MK 7240 in participants of any sex/gender aged 16 to 75 (inclusive) with moderately to severely active CD. While this “master” protocol includes common operational elements for both Study 1 and Study 2, randomization, data collection, statistical analyses, and data reporting will be conducted for each study independently. Each study has its own objectives and ...

GO TO STUDY Go

Cancer and neoplasms

DS6000-109 - A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Dose Optimization and Phase 3 Study of R-DXd versus Investigator’s Choice of Chemotherapy in Platinum resistant Ovarian Cancer)

This is a global, multicenter, randomized, open-label, Phase 2/3 study in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer who have received at least 1 and no more than 3 prior systemic lines of anticancer therapy. In this operationally seamless design, data from Phase 2 will not be utilized for the primary analysis in Phase 3 to strictly control the type I error in Phase 3. Phase 2 Study Design The Phase 2 part of this study is designed ...

GO TO STUDY Go

Inflammatory and immune system

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet’s Disease (BEAN)

Behçet's disease (BD) is an inflammatory condition that causes damages of the blood vessels affecting many parts of the body. The disease is characterized by intermittent symptoms of varying severity across almost all organ systems and oral ulcers, considered the most common sign at the onset of BD and are observed in nearly every patient The treatment of BD is generally based on experience, and the drug of choice is based on specific clinical signs and symptoms in each patient. The ...

GO TO STUDY Go

Neurological Oral and Gastrointestinal

A Prospective, Observational Cohort Study to Assess Long-Term Safety in Patients Prescribed Epidyolex® with a Focus on Drug-induced Liver Injury (DILI)

This is a multicentre, prospective, non-interventional observational cohort study of patients who are planned to receive, or already receiving Epidyolex under real-world conditions of clinical care. This study is designed to address a Pharmacovigilance Risk Assessment Committee (PRAC) request to conduct a Category 3 Post-Authorisation Safety Study (PASS), as requested in the Risk Management Plan (RMP) at the time of approval. While 12 safety concerns were noted in the RMP, PRAC emphasis was on the need to further characterize the ...

GO TO STUDY Go

Blood Reproductive health and childbirth

A phase III, multi-centre, randomised placebo-controlled trial of oral iron supplementation for the prevention of maternal anaemia

The study hypothesis is that a strategy of universal primary prevention of anaemia during pregnancy with oral iron supplementation will impact the composite primary outcome of pre-term birth,stillbirth,neonatal death and small for gestational age (SGA).

GO TO STUDY Go